• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 20-F filed by Global Cord Blood Corporation

    8/11/23 4:01:10 PM ET
    $CO
    Managed Health Care
    Health Care
    Get the next $CO alert in real time by email
    NT 20-F 1 12b.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    FORM 12b-25

    NOTIFICATION OF LATE FILING
    SEC File Number: 001-34541
    CUSIP Number:   G39342103 

    (Check One):  ☐ Form 10-K ☑ Form 20-F ☐ Form 11-K  ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
    For Period Ended: March 31, 2023
    ☐ Transition Report on Form 10-K
    ☐ Transition Report on Form 20-F
    ☐ Transition Report on Form 11-K
    ☐ Transition Report on Form 10-Q
    For the Transition Period Ended:
                     
     
     
     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A


    Part I - Registrant Information
                     
     
     
     
     Global Cord Blood Corporation
    Full Name of Registrant
     
    N/A
    Former Name if Applicable
     
    48th Floor. Bank of China Tower
    1 Garden Road
    Central
    Hong Kong S.A.R.
    Address of Principal Executive Office (Street and Number)
     
     
     





    Part II - Rules 12b-25(b) and (c)
    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

               
     
    (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
     
     ☐ 
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
     
     
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

    Part III - Narrative
    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

    On September 22, 2022, the Grand Court of the Cayman Islands (the “Court”) issued an order appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited, as joint provisional liquidators (the “JPLs”) of Global Cord Blood Corporation (the “Company”) pursuant to Section 104(2) of the Companies Act (as amended) of the Cayman Islands.

    Since their appointment, the JPLs have furnished four reports on their work to the Court (on October 21, 2022, December 1, 2022, March 1, 2023 and June 1, 2023), copies of which are available on the Company’s website https://ir.globalcordbloodcorporation.com, as well as on the JPLs’ estate portal:  https://www.grantthornton.ca/en/service/advisory/creditor-updates/#Global-Cord-Blood-

    As the JPLs’ investigations into the Company’s financial position is ongoing, the Company was unable to timely file its Annual Report on Form 20-F for the Company’s fiscal year ended March 31, 2023 (the 2023 Annal Report”) without unreasonable effort or expense. The Company cannot at this time estimate the anticipated filing date of the 2023 Annual Report.

    Part IV - Other Information
    (1) Name and telephone number of person to contact in regard to this notification
     


    Margot MacInnis
     345
    949 7100
    (Name)
    (Area Code)
    (Telephone Number)

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ☑ Yes ☐ No

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?   ☑ Yes ☐ No


    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

    As the JPLs’ investigations into the Company’s financial position is ongoing, the Company cannot at this time estimate the extent of any change in results of operations from the fiscal year ended March 31, 2022 that would be reflected by the earnings statements to be included in the 2023 Annual Report.









    Global Blood Cord Corporation
    (Name of Registrant as Specified in Charter)

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.



    Date: August 11, 2023
     


     
    By: 
    /S/ Margot MacInnis
     
     
    Margot Macinnis
    Joint Provisional Liquidator by Order of the Grand Court of the Cayman Islands
     


    Get the next $CO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GLOBAL CORD BLOOD CORPORATION ANNOUNCES FAILURE TO FILE INTERIM FINANCIALS

    GEORGE TOWN, Cayman Islands and HONG KONG, April 13, 2023 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), a provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services in China, announced that it received a notice (the "Notice") on April 3, 2023 from the New York Stock Exchange ("NYSE") with respect to its failure to timely file on Form 6-K its semi-annual financials for the six-month period ended September 30, 2022 (the "Interim Financials") as required by NYSE Listing Standard 203.03. As previously announced, on September 22, 2022, the Grand Court of the Cayman Islands issued an order (the "Order") appoi

    4/13/23 3:08:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

    9/26/22 4:07:00 PM ET
    $CO
    Managed Health Care
    Health Care

    The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

    9/23/22 1:52:00 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    SEC Filings

    View All

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    2/12/24 5:06:46 PM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    12/4/23 5:15:19 PM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    9/29/23 4:33:27 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Financials

    Live finance-specific insights

    View All

    Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022

    Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ($24.3 Million) HONG KONG, July 5, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022.

    7/5/22 4:16:00 PM ET
    $CO
    $INCY
    Managed Health Care
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022

    Added 18,985 New Subscribers in 3Q22Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million)         Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million)Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Million)Conference Call to be Held on March 1, 2022, at 8:00 a.m. ET HONG KONG, Feb. 28, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine month

    2/28/22 4:16:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2022 Financial Results

    HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release its financial results for the third quarter and first nine months of fiscal 2022 on Monday, February 28, 2022, after the U.S. market close.  The Company will host a conference call at 8:00 a.m. ET on Tuesday, March 1, 2022 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through

    2/23/22 7:00:00 AM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Leadership Updates

    Live Leadership Updates

    View All

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

    9/26/22 4:07:00 PM ET
    $CO
    Managed Health Care
    Health Care

    The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

    9/23/22 1:52:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting

    HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual General Meeting of shareholders, held on December 7, 2021, in Hong Kong S.A.R., China. At the Annual General Meeting, the Company's shareholders ratified the re-appointment of KPMG Huazhen LLP as independent auditors of the Company for the financial year ending March 31, 2022, and authorized any duly formed committee of the directors to fix the remuneration of the independent auditors; and re-elected Ms.

    12/7/21 8:32:00 AM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

    2/14/24 10:15:21 AM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form SC 13G filed by Global Cord Blood Corporation

    SC 13G - Global Cord Blood Corp (0001467808) (Subject)

    2/14/23 10:23:43 AM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

    2/3/23 2:38:38 PM ET
    $CO
    Managed Health Care
    Health Care